DNB Bioteknologi A
Equity fund
1 year
USA
Largest region
High
Risk
Annual costs
Morningstar
Partial
Sustainability
Development
Last 5 years
( ann.)
Description
- Fondet er et aksjefond som investerer hovedsakelig i aksjer (verdipapirer som representerer en eierandel i et selskap) notert på børser og regulerte markeder over hele verden, innenfor sektorene bioteknologi, diagnostikk, farmasi, produksjon av farmasøytiske produkter, biologiske legemidler herunder genterapi, og annen helserelatert virksomhet. Det vil også være anledning til å investere innenfor selskaper som har deler av sitt virke tilknyttet helse.
Investment horizon
- DNB Bioteknologi A is a Equity fund. This mutual fund type is suitable for those who plan to save for at least 6 years.
Characteristics
- Minimum amount
- Sharpe 3 years
- Price/NAV
25 Jun 2025
- Start date04 May 2020
- ISINNO0010877707
Risk
- High (5 of 7)
Morningstar rating
- The Morningstar Rating is an objective standard that tells us how well a fund has done compared to similar funds. If a fund performs better than other funds it is compared with, it receives a high rating. Correspondingly, a fund receives a low rating if it performs worse than similar funds.
Sustainability
- SustainabilityPartial
Costs
- Ongoing costs
Includes management fees of 0,85 %
- Platform fee
- Kickback fee
- Annual running costs
- Performance-based fee
Any transaction costs to the manager are not included in the cost overview. These are stated under cost details on the summary page before you purchase the fund. Costs for any currency exchanges are not included.
Allocation
- Stocks 98%Interest 2%
Portfolio
Shows the fund's largest investments.
- argenx SE7.0%
- Biomarin Pharmaceutical Inc6.3%
- Vertex Pharmaceuticals Inc4.4%
- Alnylam Pharmaceuticals Inc4.3%
- Neurocrine Biosciences Inc4.0%
- Xenon Pharmaceuticals Inc3.7%
- Amgen Inc3.5%
- Ascendis Pharma AS ADR3.3%
- Exact Sciences Corp3.2%
- Axsome Therapeutics Inc3.1%